Systematic module approach identifies altered genes and pathways in four types of ovarian cancer

Liu,Jing; Wang,Hui‑Ling; Ma,Feng‑Mei; Guo,Hong‑Ping; Fang,Ning‑Ning; Wang,Shan‑Shan; Li,Xin‑Hong

doi:10.3892/mmr.2017.7649

Systematic module approach identifies altered genes and pathways in four types of ovarian cancer

Authors:
- Jing Liu
- Hui‑Ling Wang
- Feng‑Mei Ma
- Hong‑Ping Guo
- Ning‑Ning Fang
- Shan‑Shan Wang
- Xin‑Hong Li
View Affiliations

Affiliations: Physical Examination Center, People's Hospital of Binzhou, Binzhou, Shandong 256610, P.R. China, Department of Gynecology, People's Hospital of Binzhou, Binzhou, Shandong 256610, P.R. China, Department of Infectious Disease, People's Hospital of Binzhou, Binzhou, Shandong 256610, P.R. China, Intensive Care Unit, People's Hospital of Binzhou, Binzhou, Shandong 256610, P.R. China, Department of Obstetrics, People's Hospital of Binzhou, Binzhou, Shandong 256610, P.R. China, Department of Internal Medicine, Jinan Central Hospital, Jinan, Shandong 250013, P.R. China
Published online on: September 28, 2017 https://doi.org/10.3892/mmr.2017.7649
Pages: 7907-7914
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to identify altered genes and pathways associated with four histotypes of ovarian cancer, according to the systematic tracking of dysregulated modules of reweighted protein‑protein interaction (PPI) networks. Firstly, the PPI network and gene expression data were initially integrated to infer and reweight normal ovarian and four types of ovarian cancer (endometrioid, serous, mucinous and clear cell carcinoma) PPI networks based on Spearman's correlation coefficient. Secondly, modules in the PPI network were mined using a clique‑merging algorithm and the differential modules were identified through maximum weight bipartite matching. Finally, the gene compositions in the altered modules were analyzed, and pathway functional enrichment analyses for disrupted module genes were performed. In five conditional‑specific networks, universal alterations in gene correlations were revealed, which leads to the differential correlation density among disrupted module pairs. The analyses revealed 28, 133, 139 and 33 altered modules in endometrioid, serous, mucinous and clear cell carcinoma, respectively. Gene composition analyses of the disrupted modules revealed five common genes (mitogen‑activated protein kinase 1, phosphoinositide 3‑kinase‑encoding catalytic 110‑KDα, AKT serine/threonine kinase 1, cyclin D1 and tumor protein P53) across the four subtypes of ovarian cancer. In addition, pathway enrichment analysis confirmed one common pathway (pathways in cancer), in the four histotypes. This systematic module approach successfully identified altered genes and pathways in the four types of ovarian cancer. The extensive differences of gene correlations result in dysfunctional modules, and the coordinated disruption of these modules contributes to the development and progression of ovarian cancer.

View Figures

View References

1	Coleman RL, Monk BJ, Sood AK and Herzog TJ: Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol. 10:211–224. 2013. View Article : Google Scholar : PubMed/NCBI
2	Fredrickson TN: Ovarian tumors of the hen. Environ Health Perspect. 73:35–51. 1987. View Article : Google Scholar : PubMed/NCBI
3	Barua A, Bitterman P, Abramowicz JS, Dirks AL, Bahr JM, Hales DB, Bradaric MJ, Edassery SL, Rotmensch J and Luborsky JL: Histopathology of ovarian tumors in laying hens: A preclinical model of human ovarian cancer. Int J Gynecol Cancer. 19:531–539. 2009. View Article : Google Scholar : PubMed/NCBI
4	Feeley KM and Wells M: Precursor lesions of ovarian epithelial malignancy. Histopathology. 38:87–95. 2001. View Article : Google Scholar : PubMed/NCBI
5	Bell DA: Origins and molecular pathology of ovarian cancer. Mod Pathol. 18 Suppl 2:S19–S32. 2005. View Article : Google Scholar : PubMed/NCBI
6	Moorman PG, Palmieri RT, Akushevich L, Berchuck A and Schildkraut JM: Ovarian cancer risk factors in African-American and white women. Am J Epidemiol. 170:598–606. 2009. View Article : Google Scholar : PubMed/NCBI
7	Sharifian A, Pourhoseingholi MA, Norouzinia M and Vahedi M: Ovarian cancer in Iranian women, a trend analysis of mortality and incidence. Asian Pac J Cancer Prev. 15:10787–10790. 2014. View Article : Google Scholar : PubMed/NCBI
8	Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, et al: Rethinking ovarian cancer: Recommendations for improving outcomes. Nat Rev Cancer. 11:719–725. 2011. View Article : Google Scholar : PubMed/NCBI
9	Lengauer C, Kinzler KW and Vogelstein B: Genetic instabilities in human cancers. Nature. 396:643–649. 1998. View Article : Google Scholar : PubMed/NCBI
10	Konstantinopoulos PA, Spentzos D and Cannistra SA: Gene-expression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol. 5:577–587. 2008. View Article : Google Scholar : PubMed/NCBI
11	Meinhold-Heerlein I, Bauerschlag D, Zhou Y, Sapinoso LM, Ching K, Frierson H Jr, Bräutigam K, Sehouli J, Stickeler E, Könsgen D, et al: An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma. Clin Cancer Res. 13:458–466. 2007. View Article : Google Scholar : PubMed/NCBI
12	Ansenberger K, Zhuge Y, Lagman JA, Richards C, Barua A, Bahr JM and Hales DB: E-cadherin expression in ovarian cancer in the laying hen, Gallus domesticus, compared to human ovarian cancer. Gynecol Oncol. 113:362–369. 2009. View Article : Google Scholar : PubMed/NCBI
13	Jackson E, Anderson K, Ashwell C, Petitte J and Mozdziak PE: CA125 expression in spontaneous ovarian adenocarcinomas from laying hens. Gynecol Oncol. 104:192–198. 2007. View Article : Google Scholar : PubMed/NCBI
14	Zhuge Y, Lagman JA, Ansenberger K, Mahon CJ, Daikoku T, Dey SK, Bahr JM and Hales DB: CYP1B1 expression in ovarian cancer in the laying hen Gallusdomesticus. Gynecol Oncol. 112:171–178. 2009. View Article : Google Scholar : PubMed/NCBI
15	Zidar N, Odar K, Glavac D, Jerse M, Zupanc T and Stajer D: Cyclooxygenase in normal human tissues-is COX-1 really a constitutive isoform and COX-2 an inducible isoform? J Cell Mol Med. 13:3753–3763. 2009. View Article : Google Scholar : PubMed/NCBI
16	Spandidos DA, Dokianakis DN, Kallergi G and Aggelakis E: Molecular basis of gynecological cancer. Ann NY Acad Sci. 900:56–64. 2000. View Article : Google Scholar : PubMed/NCBI
17	Cancer Genome Atlas Research Network, . Integrated genomic analyses of ovarian carcinoma. Nature. 474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI
18	Lafky JM, Wilken JA, Baron AT and Maihle NJ: Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta. 1785:232–265. 2008.PubMed/NCBI
19	Li Q, Zeng X, Cheng X, Zhang J, Ji J, Wang J, Xiong K, Qi Q and Huang W: Diagnostic value of dual detection of hepatocyte nuclear factor 1 beta (HNF-1beta) and napsin A for diagnosing ovarian clear cell carcinoma. Int J Clin Exp Pathol. 8:8305–8310. 2015.PubMed/NCBI
20	Gavin AC, Aloy P, Grandi P, Krause R, Boesche M, Marzioch M, Rau C, Jensen LJ, Bastuck S, Dümpelfeld B, et al: Proteome survey reveals modularity of the yeast cell machinery. Nature. 440:631–636. 2006. View Article : Google Scholar : PubMed/NCBI
21	Jordán F, Nguyen TP and Liu WC: Studying protein-protein interaction networks: A systems view on diseases. Brief Funct Genomics. 11:497–504. 2012. View Article : Google Scholar : PubMed/NCBI
22	Wu C, Zhu J and Zhang X: Integrating gene expression and protein-protein interaction network to prioritize cancer-associated genes. BMC Bioinformatics. 13:1822012. View Article : Google Scholar : PubMed/NCBI
23	Srihari S and Ragan MA: Systematic tracking of dysregulated modules identifies novel genes in cancer. Bioinformatics. 29:1553–1561. 2013. View Article : Google Scholar : PubMed/NCBI
24	Hendrix ND, Wu R, Kuick R, Schwartz DR, Fearon ER and Cho KR: Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res. 66:1354–1362. 2006. View Article : Google Scholar : PubMed/NCBI
25	Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 4:249–264. 2003. View Article : Google Scholar : PubMed/NCBI
26	Nguyen PV, Srihari S and Leong HW: Identifying conserved protein complexes between species by constructing interolog networks. BMC Bioinformatics. 14 Suppl 16:S82013. View Article : Google Scholar : PubMed/NCBI
27	Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
28	Liu G, Wong L and Chua HN: Complex discovery from weighted PPI networks. Bioinformatics. 25:1891–1897. 2009. View Article : Google Scholar : PubMed/NCBI
29	Tomita E, Tanaka A and Takahashi H: The worst-case time complexity for generating all maximal cliques and computational experiments. Theoret Comput Sci. 363:28–42. 2006. View Article : Google Scholar
30	Benjamini Y, Drai D, Elmer G, Kafkafi N and Golani I: Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 125:279–284. 2001. View Article : Google Scholar : PubMed/NCBI
31	da W Huang, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 4:44–57. 2009.PubMed/NCBI
32	Chen J, Bai M, Ning C, Xie B, Zhang J, Liao H, Xiong J, Tao X, Yan D, Xi X, et al: Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1alpha/cyclin D1 pathway. Oncogene. 35:2506–2517. 2016. View Article : Google Scholar : PubMed/NCBI
33	Kim YS, Choi KC and Hwang KA: Genistein suppressed epithelial-mesenchymal transition and migration efficacies of BG-1 ovarian cancer cells activated by estrogenic chemicals via estrogen receptor pathway and downregulation of TGF-β signaling pathway. Phytomedicine. 22:993–999. 2015. View Article : Google Scholar : PubMed/NCBI
34	Tong X, Barbour M, Hou K, Gao C, Cao S, Zheng J, Zhao Y, Mu R and Jiang HR: Interleukin-33 predicts poor prognosis and promotes ovarian cancer cell growth and metastasis through regulating ERK and JNK signaling pathways. Mol Oncol. 10:113–125. 2016. View Article : Google Scholar : PubMed/NCBI
35	Wang Q, Tang Y, Yu H, Yin Q, Li M, Shi L, Zhang W, Li D and Li L: CCL18 from tumor-cells promotes epithelial ovarian cancer metastasis via mTOR signaling pathway. Mol Carcinog. 55:1688–1699. 2016. View Article : Google Scholar : PubMed/NCBI
36	Su YQ, Wigglesworth K, Pendola FL, O'Brien MJ and Eppig JJ: Mitogen-activated protein kinase activity in cumulus cells is essential for gonadotropin-induced oocyte meiotic resumption and cumulus expansion in the mouse. Endocrinology. 143:2221–2232. 2002. View Article : Google Scholar : PubMed/NCBI
37	Guadagno TM and Ferrell JE Jr: Requirement for MAPK activation for normal mitotic progression in Xenopus egg extracts. Science. 282:1312–1315. 1998. View Article : Google Scholar : PubMed/NCBI
38	Gao Y, Ren J, Zhang L, Zhang Y, Wu X, Jiang H, Xu F, Yuan B, Yu X and Zhang J: The effects of demecolcine, alone or in combination with sucrose on bovine oocyte protrusion rate, MAPK1 protein level and c-mos gene expression level. Cell Physiol Biochem. 34:1974–1982. 2014. View Article : Google Scholar : PubMed/NCBI
39	Posada J, Yew N, Ahn NG, Woude GF Vande and Cooper JA: Mos stimulates MAP kinase in Xenopus oocytes and activates a MAP kinase kinase in vitro. Mol Cell Biol. 13:2546–2553. 1993. View Article : Google Scholar : PubMed/NCBI
40	Shibuya EK and Ruderman JV: Mos induces the in vitro activation of mitogen-activated protein kinases in lysates of frog oocytes and mammalian somatic cells. Mol Biol Cell. 4:781–790. 1993. View Article : Google Scholar : PubMed/NCBI
41	Huang N, Wang J, Xie W, Lyu Q, Wu J, He J, Qiu W, Xu N and Zhang Y: MiR-378a-3p enhances adipogenesis by targeting mitogen-activated protein kinase 1. Biochem Biophys Res Commun. 457:37–42. 2015. View Article : Google Scholar : PubMed/NCBI
42	Yao R and Cooper GM: Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science. 267:2003–2006. 1995. View Article : Google Scholar : PubMed/NCBI
43	Liang J and Slingerland JM: Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle. 2:339–345. 2003. View Article : Google Scholar : PubMed/NCBI
44	Lee CM, Fuhrman CB, Planelles V, Peltier MR, Gaffney DK, Soisson AP, Dodson MK, Tolley HD, Green CL and Zempolich KA: Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines. Clin Cancer Res. 12:250–256. 2006. View Article : Google Scholar : PubMed/NCBI
45	Keysar SB, Astling DP, Anderson RT, Vogler BW, Bowles DW, Morton JJ, Paylor JJ, Glogowska MJ, Le PN, Eagles-Soukup JR, et al: A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol Oncol. 7:776–790. 2013. View Article : Google Scholar : PubMed/NCBI
46	Bertelsen BI, Steine SJ, Sandvei R, Molven A and Laerum OD: Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: Frequent PIK3CA amplification and AKT phosphorylation. Int J Cancer. 118:1877–1883. 2006. View Article : Google Scholar : PubMed/NCBI
47	Datta SR, Brunet A and Greenberg ME: Cellular survival: A play in three Akts. Genes Dev. 13:2905–2927. 1999. View Article : Google Scholar : PubMed/NCBI
48	Won HS, Jung CK, Chun SH, Kang JH, Kim YS, Sun DI and Kim MS: Difference in expression of EGFR, pAkt, and PTEN between oropharyngeal and oral cavity squamous cell carcinoma. Oral Oncol. 48:985–990. 2012. View Article : Google Scholar : PubMed/NCBI
49	Chalhoub N and Baker SJ: PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 4:127–150. 2009. View Article : Google Scholar : PubMed/NCBI
50	Zhang S and Yu D: PI(3)king apart PTEN's role in cancer. Clin Cancer Res. 16:4325–4330. 2010. View Article : Google Scholar : PubMed/NCBI
51	Arnold A and Papanikolaou A: Cyclin D1 in breast cancer pathogenesis. J Clin Oncol. 23:4215–4224. 2005. View Article : Google Scholar : PubMed/NCBI
52	Motokura T, Bloom T, Kim HG, Jüppner H, Ruderman JV, Kronenberg HM and Arnold A: A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature. 350:512–515. 1991. View Article : Google Scholar : PubMed/NCBI
53	Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A and Schmidt EV: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature. 369:669–671. 1994. View Article : Google Scholar : PubMed/NCBI
54	Worsley SD, Ponder BA and Davies BR: Overexpression of cyclin D1 in epithelial ovarian cancers. Gynecol Oncol. 64:189–195. 1997. View Article : Google Scholar : PubMed/NCBI
55	Sui L, Tokuda M, Ohno M, Hatase O and Hando T: The concurrent expression of p27(kip1) and cyclin D1 in epithelial ovarian tumors. Gynecol Oncol. 73:202–209. 1999. View Article : Google Scholar : PubMed/NCBI
56	Vousden KH and Prives C: Blinded by the light: The growing complexity of p53. Cell. 137:413–431. 2009. View Article : Google Scholar : PubMed/NCBI
57	Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI
58	Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, Butts M and Godwin AK: Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management. Mol Oncol. 3:97–137. 2009. View Article : Google Scholar : PubMed/NCBI
59	Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El-Naggar A, Minguillon C, Schönborn I, et al: Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res. 7:2984–2997. 2001.PubMed/NCBI
60	Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P and Verheijen RH: Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 195:451–456. 2001. View Article : Google Scholar : PubMed/NCBI
61	Lu D, Kuhn E, Bristow RE, Giuntoli RL II, Kjaer SK, Shih IeM and Roden RB: Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol Oncol. 122:560–566. 2011. View Article : Google Scholar : PubMed/NCBI